|
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Therefore, activation of major compensatory angiogenic pathways, sustaining tumor angiogenesis during VEGF blockade contributing to the recurrence of tumor growth overcome antiangiogenic strategies.
|
29184575 |
2017 |
|
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Targeting the vascular endothelial growth factor signaling axis in glioblastoma inevitably leads to tumor recurrence and a more aggressive phenotype.
|
27787897 |
2017 |
|
Recurrent tumor
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The present study aimed to investigate the expression of hypoxia inducible factor-2 subunit α (HIF-2α), vascular endothelial growth factor A (VEGFA), erythropoietin-producing hepatocellular A2 (EphA2) and angiogenesis in residual hepatocellular carcinoma (HCC), following treatment with high-intensity focused ultrasound (HIFU) ablation, in order to investigate the association between protein expression and tumor recurrence and growth.
|
28587437 |
2017 |
|
Recurrent tumor
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Tumor recurrence was significantly more frequent in NSCLC patients with survivin and VEGF mRNA positivity postoperation than in patients without (P = 0.003 and P = 0.006, respectively).
|
23756092 |
2013 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The homozygous genotype VEGF -2578 AA had significant effect on time to tumor recurrence (hazard ratio [HR] = 2.01 [95% CI: 1.13-3.56]; p = 0.02) as well as -460TT (HR = 0.50 [95% CI: 0.29-0.89]; p = 0.02).
|
22594508 |
2012 |
|
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Antiangiogenic therapy with the humanized VEGF antibody bevacizumab reduces GBM tumor growth; however, the clinical benefits are transient and invariably followed by tumor recurrence.
|
22393126 |
2012 |
|
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Polymorphisms in IL1B, IL1RN, and VEGFA as well as IL1B/IL1RN haplotype analysis may serve as molecular markers for tumor recurrence in stage II colon cancer, indicating that the analysis of angiogenesis-related gene polymorphisms may help to identify patient subgroups at high risk for tumor recurrence.
|
18987561 |
2009 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Therefore, we investigated association of VEGF genomic polymorphisms with risk for developing HCC and tumor recurrence after LT.
|
20082870 |
2009 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.
|
18550579 |
2008 |
|
Recurrent tumor
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We hypothesized that the expression of VEGF may cause tumor recurrence after PDT and exert unfavorable effect against the anti-tumor activity of ATX-s10-PDT.
|
17671719 |
2007 |
|
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
None of expression of maspin, mutant-type p53, and VEGF was significantly correlated with tumor recurrence (p=0.34, 0.56, and 0.33, respectively) and survival.
|
17174141 |
2007 |
|
Recurrent tumor
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Our results suggest that COX-2 expression correlates with VEGF expression and might be a useful prognostic factor for more frequent tumor recurrence in ESCC patients undergoing neoadjuvant CRT.
|
17511025 |
2007 |
|
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These observations suggest that VEGF may play a role in the development of ovarian cancer and that the elevated gonadotropins, as found in menopause and in most ovarian cancer patients after surgery, could accelerate tumor growth and tumor recurrence by inducing VEGF expression in OETs.
|
11774259 |
2002 |